Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(262 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1522 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Anbenitamab
CAS:<p>Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.</p>Cor e Forma:LiquidDepatuxizumab
CAS:<p>Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, inhibit tumor growth,GBM,SCCHN.</p>Pureza:95%Cor e Forma:LiquidElgemtumab
CAS:<p>Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.</p>Pureza:95%Cor e Forma:LiquidZanidatamab
CAS:<p>Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor</p>Cor e Forma:LiquidIzalontamab
CAS:<p>Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.</p>Pureza:95%+ - 95%+Cor e Forma:LiquidTovetumab
CAS:<p>Tovetumab (MEDI-575) is an anti-PDGFRα mAb inhibiting its signaling, in trials for glioblastoma and NSCLC.</p>Pureza:95%Cor e Forma:LiquidFaricimab
CAS:<p>Faricimab,Bispecific antibody targeting Ang-2/VEGF-A. Prevents retinal I/R injury. Improves vision in w-AMD, DME, RVO.</p>Pureza:95% - 95%Cor e Forma:LiquidAnti-Mouse VEGFR-2 Antibody (DC101)
<p>Anti-Mouse VEGFR-2 Antibody (DC101) is a rat-derived monoclonal antibody against mouse VEGFR2/KDR/Flk-1, serving as a mouse analogue of ramucirumab.</p>Pureza:99%Cor e Forma:Odour LiquidZalutumumab
CAS:<p>Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).</p>Pureza:95%Cor e Forma:LiquidDasatinib-d8
CAS:Dasatinib D8 is deuterium-labeled dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.Fórmula:C22H26ClN7O2SPureza:98%Cor e Forma:SolidPeso molecular:496.06Ibrutinib-d5
CAS:<p>Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.</p>Fórmula:C25H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:445.53ZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Cor e Forma:SolidPeso molecular:331.45GZD856 formic
CAS:<p>GZD856 formic inhibits PDGFRα/β (IC50: 68.6, 136.6 nM) & Bcr-Abl (IC50: 19.9, 15.4 nM), with antitumor properties.</p>Fórmula:C30H29F3N6O3Cor e Forma:SolidPeso molecular:578.58ALK5-IN-79
CAS:<p>ALK5-IN-79 (compound 57), an ALK inhibitor, exhibits anticancer activity by inhibiting the TGF-β1/SMAD signaling pathway. It effectively reduces the production of extracellular matrix (ECM) and collagen deposition. Moreover, ALK5-IN-79 demonstrates satisfactory pharmacokinetic (PK) properties and favorable in vivo tolerance.</p>Fórmula:C23H27N7OCor e Forma:SolidPeso molecular:417.51ZM323881 hydrochloride
CAS:ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.Fórmula:C22H19ClFN3O2Pureza:99.43%Cor e Forma:SolidPeso molecular:411.86EGFR-IN-117
CAS:<p>EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutations, specifically targeting the tumor environment and inducing apoptosis in cancer cells. This compound effectively inhibits the proliferation of H1975, PC-9, and mutant EGFR cells including BaF3-EGFRL858R/T790M/C797S and BaF3–C797S/Del19/T790M, with IC50 values of 13 nM, 19 nM, 1.2 nM, and 1.3 nM respectively. Additionally, EGFR-IN-117 demonstrates anti-tumor activity in mouse models.</p>Fórmula:C25H30BrN7O2SCor e Forma:SolidPeso molecular:572.52Erlotinib mesylate
CAS:<p>Erlotinib: reversible inhibitor binding to ATP site of epidermal growth factor receptor.</p>Fórmula:C23H27N3O7SPureza:98%Cor e Forma:SolidPeso molecular:489.54HVH-2930
CAS:<p>HVH-2930 is an inhibitor of Heat Shock Protein 90 (HSP90). It suppresses the cell viability of BT474 (Trastuzumab sensitive) and JIMT-1 (Trastuzumab resistant) by downregulating HSP90 client proteins such as HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin, with IC50 values of 6.86 μM and 4.42 μM, respectively. Additionally, HVH-2930 demonstrates antitumor efficacy in a mouse model and exhibits favorable pharmacokinetic properties in vivo.</p>Fórmula:C29H36N4O3Cor e Forma:SolidPeso molecular:488.62MAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Fórmula:C20H11Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:380.23AD1058
CAS:<p>AD1058 is a selective ATR inhibitor that crosses the blood-brain barrier with in vivo anticancer activity, used in the study of brain and CNS metastasis.</p>Fórmula:C19H20N6O3SPureza:98.24%Cor e Forma:SolidPeso molecular:412.47IGF-1R modulator 1
CAS:<p>IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.</p>Fórmula:C22H17N3O4Cor e Forma:SolidPeso molecular:387.39(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37EGFR-IN-109
CAS:<p>EGFR-IN-109 (compound 4), an EGFR inhibitor, displays IC 50 values of 25.8 nM for EGFR WT and 182.3 nM for EGFR T790M. This compound halts the growth of cancer cells at the G2/M phase and triggers both early and late apoptosis. It is applicable in cancer research [1].</p>Fórmula:C12H16N4OSCor e Forma:SolidPeso molecular:264.35Tyrphostin AG 112
CAS:Produto Controlado<p>Applications Tyrphostin AG 112 is an EGFR inhibitor.<br></p>Fórmula:C13H8N4OCor e Forma:NeatPeso molecular:236.232,3-Naphthalic Anhydride
CAS:Produto Controlado<p>Stability Moisture Sensitive<br>Applications 2,3-Naphthalic anhydride is used as a reagent to synthesize analogues of Thalidomide (T338850), an inhibitor of tumour necrosis factor that was once abandoned because it caused birth defects, but is currently used as an inhibitor of angiogenesis in patients with multiple myeloma.<br>References D’Amato, R., et al.: Proc. Nat. Acad. Sci., 91, 4082 (1994); Ehrenpreis, E., et al.: Gastroenterology, 117, 1271 (1999); Parma, T., et al.: Nat. Med., 5, 582 (1999); Singhal, S., et al.: New Engl. J. Med., 341, 1565 (1999)<br></p>Fórmula:C12H6O3Cor e Forma:NeatPeso molecular:198.17N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine
CAS:Produto ControladoFórmula:C20H16FN5O3Cor e Forma:Light Yellow To YellowPeso molecular:393.374-Fmoc-3(R)-morpholinecarboxylic Acid
CAS:Produto Controlado<p>Applications 4-Fmoc-3(R)-morpholinecarboxylic Acid is used to prepare 125I-labeled morpholine-containing RGD ligand of αvβ3 integrin as angiogenesis imaging probe.<br>References Bianchini, F., et al.: J. Med. Chem., 55, 5024 (2012)<br></p>Fórmula:C20H19NO5Cor e Forma:NeatPeso molecular:353.37Atrasentan
CAS:Produto Controlado<p>Applications Atrasentan is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.<br>References Bax, W., et al.: Trends Pharmacol. Sci., 15, 379 (1994); Winn, M., et al.: J. Med. Chem., 39, 1039 (1996); Wu-Wong, J., et al.: J. Pharmacol. Exp. Ther., 281, 791 (1997);<br></p>Fórmula:C29H38N2O6Cor e Forma:Off-WhitePeso molecular:510.62LB 42708
CAS:Produto Controlado<p>Applications LB 42708 is a selective nonpeptidic Farnesyltransferase (FTase) inhibitor.LB42708 suppresses tumor growth and tumor angiogenesis in both xenograft tumor models of Ras-mutated HCT116 cells and its wild-type Caco-2 cells, indicating its potential application in the treatment of both Ras-mutated and wild type tumors.<br>References Kim, C., et. al.: Mol. Pharmacol., 78, 142 (2010)<br></p>Fórmula:C30H27BrN4O2Cor e Forma:NeatPeso molecular:555.46Dehydrodivanillin (~90%, contains up to 10% unknown inorganics)
CAS:Fórmula:C16H14O6Cor e Forma:NeatPeso molecular:302.2792-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide
CAS:Produto Controlado<p>Applications 2-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide is an intermediate Apatinib 25-N-Oxide (A726160), a metabolite of the antiangiogenic agent and selective VEGFR2 inhibitor Apatinib (A726150).<br></p>Fórmula:C18H16ClN3OCor e Forma:NeatPeso molecular:325.79Tyrphostin AG 1478
CAS:Produto Controlado<p>Applications Tyrphostin AG 1478 is a potent and selective inhibitor of EGFR.<br></p>Fórmula:C16H14ClN3O2Cor e Forma:NeatPeso molecular:315.75Des-(4-(dimethylamino)-2-butenoyl)-Neratinib
CAS:Produto Controlado<p>Applications 6-Amino-4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinoline-3-carbonitrile, is used in the synthetic preparation of aminopropanamides which is used in irreversible inhibition of epidermal growth factor receptor (EGFR) for potential use in cancer therapy.<br>References Carmi, C., et al.: J. Med. Chem., 55, 2251 (2012)<br></p>Fórmula:C24H20ClN5O2Cor e Forma:NeatPeso molecular:445.9Pulsatilla Saponin D (90%)
CAS:Produto Controlado<p>Applications Pulsatilla Saponin D shows antiangiogenic and antitumor activity.<br>References Sang-Won, H. et al.: Carcinogen., 34, 2156 (2013);<br></p>Fórmula:C47H76O17Pureza:90%Cor e Forma:NeatPeso molecular:913.1Bucillamine
CAS:<p>Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.</p>Fórmula:C7H13NO3S2Pureza:99.47%Cor e Forma:SolidPeso molecular:223.31E3330
CAS:<p>E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.</p>Fórmula:C21H30O6Pureza:99.52%Cor e Forma:SolidPeso molecular:378.46pan-HER-IN-2
CAS:<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Fórmula:C19H15BrClN5OCor e Forma:SolidPeso molecular:444.71EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Fórmula:C28H30N4O3Cor e Forma:SolidPeso molecular:470.56AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Fórmula:C24H34N8O2SCor e Forma:SolidPeso molecular:498.64EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SCor e Forma:SolidPeso molecular:711.68PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Fórmula:C26H39N9Cor e Forma:SolidPeso molecular:477.65LRRK2/NUAK1/TYK2-IN-1
CAS:<p>LRRK2/NUAK1/TYK2-IN-1 inhibits LRRK2, TYK2, NUAK1 with IC50 < 10 nM, useful in autoimmune research.</p>Fórmula:C20H11F3N6Cor e Forma:SolidPeso molecular:392.34EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Cor e Forma:SolidPeso molecular:564.51CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Fórmula:C28H26F3N7O2Cor e Forma:SolidPeso molecular:549.55EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Fórmula:C25H25ClFN5O4Cor e Forma:SolidPeso molecular:513.95TL02-59 dihydrochloride
CAS:<p>TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).</p>Fórmula:C32H36Cl2F3N5O4Pureza:98%Cor e Forma:SolidPeso molecular:682.56Ebselen oxide
CAS:<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Fórmula:C13H9NO2SePureza:98%Cor e Forma:SolidPeso molecular:290.18Momelotinib Mesylate
CAS:<p>Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.</p>Fórmula:C24H26N6O5SPureza:98%Cor e Forma:SolidPeso molecular:510.57SMU-B
CAS:<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Fórmula:C26H25Cl2FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:515.41ER 27319 maleate
CAS:<p>Selective inhibitor of Syk kinase</p>Fórmula:C22H24N2O5Pureza:98%Cor e Forma:SolidPeso molecular:396.44BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Fórmula:C27H28N6O2Cor e Forma:SolidPeso molecular:468.55EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Fórmula:C19H12BrClO2Cor e Forma:SolidPeso molecular:387.65Ficonalkib
CAS:<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Fórmula:C29H39N7O3SCor e Forma:SolidPeso molecular:565.73FLT3-IN-17
CAS:<p>FLT3-IN-17: FAK inhibitor, IC50 of 12 nM; blocks CYPs, FLT3 mutants; IC50 <0.5 nM for D835Y in cancer studies.</p>Fórmula:C23H24N6O2S2Cor e Forma:SolidPeso molecular:480.61Multi-kinase-IN-2
CAS:<p>Orally active Multi-kinase-IN-2 blocks angiokinases including VEGFR, PDGFR, FGFR, and more, reducing AKT/ERK phosphorylation and promoting apoptosis.</p>Fórmula:C34H35N5O3Cor e Forma:SolidPeso molecular:561.67VEGFR-2-IN-6
CAS:<p>VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis [1].</p>Fórmula:C20H21N7O2SPureza:99.01%Cor e Forma:SolidPeso molecular:423.49YH-306
CAS:<p>YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.</p>Fórmula:C19H18N2O2Pureza:98.06%Cor e Forma:SolidPeso molecular:306.36EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Cor e Forma:SolidPeso molecular:351.4KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Cor e Forma:SolidPeso molecular:327.33GZD856
CAS:GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.Fórmula:C29H27F3N6OPureza:98%Cor e Forma:SolidPeso molecular:532.56PDGFRα kinase inhibitor 1
CAS:PDGFRα kinase inhibitor 1 is a type II PDGFRα kinase inhibitor that inhibits both PDGFRα and PDGFRβ.Fórmula:C34H34N8O2Pureza:99.78%Cor e Forma:SolidPeso molecular:586.69Atopaxar Hydrobromide
CAS:Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.Fórmula:C29H39BrFN3O5Pureza:98%Cor e Forma:SolidPeso molecular:608.54TG 100801 Hydrochloride
CAS:<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Fórmula:C33H31Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:616.54Tyk2-IN-5
CAS:Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).Fórmula:C21H19FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:434.43PHM16
CAS:<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Fórmula:C20H22N6O4Pureza:98%Cor e Forma:SolidPeso molecular:410.43BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Fórmula:C26H24N10O2Cor e Forma:SolidPeso molecular:508.53ProMMP-9 inhibitor-3c
CAS:<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Fórmula:C18H20FN3O2SCor e Forma:SolidPeso molecular:361.43XST-14
CAS:<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Fórmula:C16H21NO4Pureza:99.84% - 99.84%Cor e Forma:SolidPeso molecular:291.34EGFR-IN-57
CAS:<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Fórmula:C22H15N3O2SCor e Forma:SolidPeso molecular:385.44CPL304110
CAS:<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Fórmula:C25H30N6O2Cor e Forma:SolidPeso molecular:446.54EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Cor e Forma:SolidPeso molecular:479.57EGFR-IN-52
CAS:<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Fórmula:C19H18N4O3SCor e Forma:SolidPeso molecular:382.44c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Fórmula:C30H20F2N4O3Cor e Forma:SolidPeso molecular:522.5MAX-40279 hemifumarate
CAS:<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Fórmula:C48H50F2N12O6S2Cor e Forma:SolidPeso molecular:993.12BCR-ABL-IN-2
CAS:<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Fórmula:C24H25Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:502.39BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Cor e Forma:SolidPeso molecular:683.8LS-104
CAS:<p>LS-104 is a JAK2 inhibitor.</p>Fórmula:C19H16N2O3Cor e Forma:SolidPeso molecular:320.34UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Cor e Forma:SolidPeso molecular:339.78VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Fórmula:C26H20Cl2F3N5O3S2Cor e Forma:SolidPeso molecular:642.5NSC 33994
CAS:<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Fórmula:C28H42N2O2Pureza:98%Cor e Forma:SolidPeso molecular:438.65JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Fórmula:C21H17BF3N5O3Cor e Forma:SolidPeso molecular:455.2EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PCor e Forma:SolidPeso molecular:759.68EL-102
CAS:EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.Fórmula:C19H16N2O3S2Pureza:99.34%Cor e Forma:SolidPeso molecular:384.47Tyrphostin AG 112
CAS:Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.Fórmula:C13H8N4OPureza:99.14%Cor e Forma:SolidPeso molecular:236.23BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Fórmula:C27H22F3N5O2Cor e Forma:SolidPeso molecular:505.49VS 8
CAS:<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Fórmula:C26H20F3N3O3Cor e Forma:SolidPeso molecular:479.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OCor e Forma:SolidPeso molecular:507.469TM-233
CAS:TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.Fórmula:C25H20O4Pureza:98%Cor e Forma:SolidPeso molecular:384.42NVP-AAD777
CAS:<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Fórmula:C22H14F6N4Pureza:98%Cor e Forma:SolidPeso molecular:448.36JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SCor e Forma:SolidPeso molecular:593.11EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Cor e Forma:SolidPeso molecular:609.76EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Cor e Forma:SolidPeso molecular:434.51NSC114792
CAS:<p>NSC114792 is a selective JAK3 inhibitor.</p>Fórmula:C26H32N4O2SPureza:98%Cor e Forma:SolidPeso molecular:464.62ALK5-IN-29
CAS:<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Fórmula:C24H25FN8Cor e Forma:SolidPeso molecular:444.51JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SCor e Forma:SolidPeso molecular:393.46FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Fórmula:C21H23F3N6OCor e Forma:SolidPeso molecular:432.44Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Fórmula:C12H12N4O5Cor e Forma:SolidPeso molecular:292.25FAK-IN-5
CAS:<p>FAK-IN-5 is a FAK signaling inhibitor that induces apoptosis and autophagy.</p>Fórmula:C29H29ClF3N3O4Cor e Forma:SolidPeso molecular:576.01JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:519.42SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Fórmula:C21H29N5O2Cor e Forma:SolidPeso molecular:383.49INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Cor e Forma:SolidPeso molecular:380.23TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SCor e Forma:SolidPeso molecular:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OCor e Forma:SolidPeso molecular:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Fórmula:C17H19N3O2Cor e Forma:SolidPeso molecular:297.35EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SCor e Forma:SolidPeso molecular:658.64DMPQ dihydrochloride
CAS:<p>PDGFRβ inhibitor</p>Fórmula:C16H16Cl2N2O2Pureza:99.51%Cor e Forma:SolidPeso molecular:339.22VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Fórmula:C17H15BrN2OCor e Forma:SolidPeso molecular:343.22PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Fórmula:C26H29Cl2N5O3Pureza:97.01%Cor e Forma:SolidPeso molecular:530.45BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Fórmula:C32H25F3N6O2Pureza:99.22% - 99.24%Cor e Forma:SolidPeso molecular:582.58BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Fórmula:C29H23F3N6O3Cor e Forma:SolidPeso molecular:560.53Atopaxar
CAS:<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H38FN3O5Pureza:97.07% - 98.07%Cor e Forma:SolidPeso molecular:527.63EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Cor e Forma:SolidPeso molecular:569.67FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Cor e Forma:SolidPeso molecular:403.43GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Cor e Forma:SolidPeso molecular:596.74TGFBR1-IN-1
CAS:TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).Fórmula:C23H17N5O2SPureza:98%Cor e Forma:SolidPeso molecular:427.48Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Cor e Forma:SolidPeso molecular:268.23TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Cor e Forma:SolidPeso molecular:429.46HS-438
CAS:<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Fórmula:C17H17N3O3SCor e Forma:SolidPeso molecular:343.4EGFR-IN-56
CAS:<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Fórmula:C23H22N4O3SCor e Forma:SolidPeso molecular:434.51PP2 Analog
CAS:PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.Fórmula:C16H17ClN4Pureza:98%Cor e Forma:SolidPeso molecular:300.79EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Fórmula:C28H28Cl2N6OCor e Forma:SolidPeso molecular:535.47ALK-IN-21
CAS:<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Fórmula:C35H45ClN6O6S4Cor e Forma:SolidPeso molecular:809.48Sch 13835
CAS:<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Fórmula:C15H10ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:335.76Cyt-PTPε Inhibitor-1
CAS:Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε.Fórmula:C19H20N4O2SPureza:99.55% - 99.82%Cor e Forma:SolidPeso molecular:368.45ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Fórmula:C17H16N2O3Cor e Forma:SolidPeso molecular:296.32VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Fórmula:C28H23N3O6SCor e Forma:SolidPeso molecular:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Fórmula:C29H29N5O5Cor e Forma:SolidPeso molecular:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Fórmula:C34H38ClFN4O7SCor e Forma:SolidPeso molecular:701.2EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Fórmula:C29H34N6O3Cor e Forma:SolidPeso molecular:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Fórmula:C31H35ClF2N8O2SCor e Forma:SolidPeso molecular:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Fórmula:C28H39N9O3SCor e Forma:SolidPeso molecular:581.73HZ-A-005
CAS:<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Fórmula:C25H23ClN6O2Cor e Forma:SolidPeso molecular:474.94VEGFR-2-IN-28
CAS:<p>VEGFR-2-IN-28 is a potent inhibitor of VEGFR-2 (IC50: 0.83 μM). VEGFR-2-IN-28 induces apoptosis and exhibits antitumor effects.</p>Fórmula:C26H17N7O7Cor e Forma:SolidPeso molecular:539.46JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Cor e Forma:SolidPeso molecular:522.55EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Cor e Forma:SolidPeso molecular:241.25ON 146040
CAS:ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.Fórmula:C24H23N7O3SPureza:97.39%Cor e Forma:SolidPeso molecular:489.55Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Fórmula:C9H9NO3Cor e Forma:SolidPeso molecular:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OCor e Forma:SolidPeso molecular:415.25MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SCor e Forma:SolidPeso molecular:1056.72EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OCor e Forma:SolidPeso molecular:285.34CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36FGFR3-IN-5
CAS:<p>FGFR3-IN-5: potent, selective FGFR3 inhibitor. IC50: 3 nM FGFR3, 44 nM FGFR2, 289 nM FGFR1. For cancer research.</p>Fórmula:C24H24FN7O3Cor e Forma:SolidPeso molecular:477.49AFG206
CAS:AFG206 is the novel first-generation type II" FLT3 inhibitor."Fórmula:C20H19N3O2Cor e Forma:SolidPeso molecular:333.38Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Fórmula:C19H18BrClN6OPureza:97.03%Cor e Forma:SolidPeso molecular:461.74S116836
CAS:<p>S116836 is a tyrosine kinase inhibitor.</p>Fórmula:C27H21F3N6OPureza:98%Cor e Forma:SolidPeso molecular:502.491,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Cor e Forma:SolidPeso molecular:557.54Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Cor e Forma:SolidPeso molecular:591.12MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Fórmula:C21H23N3OSPureza:98%Cor e Forma:SolidPeso molecular:365.49HIV-IN-6
CAS:<p>HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.</p>Fórmula:C20H16N4O3SPureza:97.12%Cor e Forma:SolidPeso molecular:392.43Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Cor e Forma:SolidPeso molecular:359.42Cenisertib
CAS:<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Fórmula:C24H30FN7OCor e Forma:SolidPeso molecular:451.54TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Fórmula:C29H31F3N8OPureza:98%Cor e Forma:SolidPeso molecular:564.6JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Cor e Forma:SolidPeso molecular:334.35MS-1020
CAS:MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.Fórmula:C21H18N2O3Pureza:98%Cor e Forma:SolidPeso molecular:346.38Tyk2-IN-7
CAS:Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).Fórmula:C18H15D3N6O3SPureza:98%Cor e Forma:SolidPeso molecular:401.46EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Fórmula:C22H18Cl2N4O2SPureza:98%Cor e Forma:SolidPeso molecular:473.37BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Cor e Forma:SolidPeso molecular:454.49FAK inhibitor 5
CAS:<p>FAK inhibitor 5 is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.</p>Fórmula:C20H21N3O2SPureza:98%Cor e Forma:SolidPeso molecular:367.46FGFR4-IN-5
CAS:<p>FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.</p>Fórmula:C23H23Cl2N5O5Cor e Forma:SolidPeso molecular:520.37DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Fórmula:C25H26ClN7O3Cor e Forma:SolidPeso molecular:507.97CAY10583
CAS:CAY10583 is a selective BLT2 agonist that increases TGF-β1 and bFGF, promotes keratinocyte migration, accelerates wound healing in diabetic mice.Fórmula:C25H25NO3Pureza:98%Cor e Forma:SolidPeso molecular:387.47PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Fórmula:C27H39N9OCor e Forma:SolidPeso molecular:505.66CHMFL-ABL/KIT-155
CAS:<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Fórmula:C33H38F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:609.68EGFR-IN-51
CAS:<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Fórmula:C21H15N3O2SCor e Forma:SolidPeso molecular:373.43BTK-IN-9
CAS:<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Fórmula:C25H19N7O4Cor e Forma:SolidPeso molecular:481.46KRC-108
CAS:<p>KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.</p>Fórmula:C20H20N6OCor e Forma:SolidPeso molecular:360.41AhR modulator-1
CAS:<p>AhR modulator-1: orally active, selective, inhibits metastasis and prostatic VEGF, anti-estrogenic in rat uterus.</p>Fórmula:C13H7Cl3OPureza:98%Cor e Forma:SolidPeso molecular:285.55PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Fórmula:C28H41N9OCor e Forma:SolidPeso molecular:519.68AG1433
CAS:<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Fórmula:C16H15ClN2O2Cor e Forma:SolidPeso molecular:302.76YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Fórmula:C24H26BrN3OPureza:98%Cor e Forma:SolidPeso molecular:452.39PD173952
CAS:<p>PD173952 is a Src kinase and Myt1 inhibitor with antitumor activity, inhibits Lyn, Abl and Csk, and induces Bcr-Abl-dependent hematopoietic cell apoptosis.</p>Fórmula:C24H21Cl2N5O2Pureza:99.5%Cor e Forma:SolidPeso molecular:482.36PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Cor e Forma:SolidPeso molecular:441.27Multi-kinase-IN-3
CAS:<p>Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).</p>Fórmula:C33H33N5O3Cor e Forma:SolidPeso molecular:547.65VEGFR-2-IN-30
<p>VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.</p>Fórmula:C28H23ClN6O4S2Cor e Forma:SolidPeso molecular:607.1JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SCor e Forma:SolidPeso molecular:413.45EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Cor e Forma:SolidPeso molecular:224.34BMS-243117
CAS:<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Fórmula:C20H21ClN4O2SCor e Forma:SolidPeso molecular:416.92FAK-IN-8
CAS:<p>FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].</p>Fórmula:C15H9Cl2N3O2SCor e Forma:SolidPeso molecular:366.22NSC-689857
CAS:<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Fórmula:C25H29NO4Pureza:98%Cor e Forma:SolidPeso molecular:407.5FIIN-4
CAS:FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.Fórmula:C35H38N8O4Pureza:99.99%Cor e Forma:SolidPeso molecular:634.73VEGFR-2-IN-21
CAS:<p>VEGFR-2-IN-21 is a potent inhibitor of VEGFR-2 (IC50: 0.10 μM) and exhibits anticancer effects.</p>Fórmula:C28H24ClN7O3SCor e Forma:SolidPeso molecular:574.05TX-1123
CAS:<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Fórmula:C20H24O3Cor e Forma:SolidPeso molecular:312.4WY-135
CAS:<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Fórmula:C28H34ClN9O3SPureza:98%Cor e Forma:SolidPeso molecular:612.15VEGFR-2-IN-22
CAS:<p>VEGFR-2-IN-22 blocks VEGFR-2/beta-tubulin, IC50=19.82 nM, induces apoptosis.</p>Fórmula:C26H24ClFN4O6Cor e Forma:SolidPeso molecular:542.94JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:543.61FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Cor e Forma:SolidPeso molecular:455.94MBM-55S
CAS:<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Fórmula:C36H39FN6O10Pureza:99.37% - 99.89%Cor e Forma:SolidPeso molecular:734.73FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Cor e Forma:SolidPeso molecular:478.54CGI560
CAS:<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Fórmula:C29H27N5OCor e Forma:SolidPeso molecular:461.56SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Cor e Forma:SolidPeso molecular:474.52FGFR-IN-7
CAS:<p>FGFR-IN-7: Oral FGFR modulator, crosses blood-brain barrier, neuroprotective, phospholipidosis-resistant, useful for neurodegeneration study.</p>Fórmula:C16H21ClF2N4O2Cor e Forma:SolidPeso molecular:374.81EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Cor e Forma:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Cor e Forma:SolidPeso molecular:480.95EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Cor e Forma:SolidPeso molecular:348.4CP-547632 hydrochloride
CAS:<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Fórmula:C20H25BrClF2N5O3SCor e Forma:SolidPeso molecular:568.86
![2-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTR%2Fthumb-webp%2FC364965.webp&w=3840&q=75)
